Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,513 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PD Clear all
Active, not recruiting Phase 2 Interventional

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Interventions
Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05785767
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
fianlimab, cemiplimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
23
States / cities
Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Suspended Phase 2Phase 3 Interventional

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

NCT04929041
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
170
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 130 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

NCT04728295
View directory record Official record
Conditions
Parkinson Disease
Interventions
Exablate 4000
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Palo Alto, California • Delray Beach, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
55
States / cities
Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jun 25, 2026, 11:34 PM EDT
Recruiting Phase 3 Interventional

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Phase 1 Interventional

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

NCT04155645
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD8233 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chula Vista, California • Glendale, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

NCT02395172
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Avelumab, Docetaxel
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
27
States / cities
Tuscaloosa, Alabama • Scottsdale , Phoenix, Arizona • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jun 25, 2026, 11:34 PM EDT
Recruiting Not applicable Interventional

Simplified, Scalable, 24-hour Adaptive DBS in Parkinson's Disease

NCT07398157
View directory record Official record
Conditions
PD - Parkinson's Disease
Interventions
Medtronic Percept Deep Brain Stimulation (cDBS), Medtronic Percept Deep Brain Stimulation (daytime aDBS), Medtronic Percept Deep Brain Stimulation (nighttime aDBS)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
41
States / cities
Prescott, Arizona • Hot Springs, Arkansas • Springdale, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects

NCT07364669
View directory record Official record
Conditions
Healthy Subjects
Interventions
Insulex® R (soluble human insulin, biosimilar), Humulin® R (soluble human insulin, biosimilar)
Drug
Lead sponsor
Laboratorios Pisa S.A. de C.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

NCT04931654
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
AZD7789
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jun 25, 2026, 11:34 PM EDT
Terminated Phase 3 Interventional Results available

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

NCT03515629
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Jun 25, 2026, 11:34 PM EDT
Not yet recruiting Phase 2 Interventional

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

NCT05253131
View directory record Official record
Conditions
MPNST, NF1, Sarcoma
Interventions
Selumetinib + ZEN-3694 ± Durvalumab
Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

NCT03440437
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
FS118, Paclitaxel
Drug
Lead sponsor
invoX Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Phase 1 Interventional

Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)

NCT01134146
View directory record Official record
Conditions
Lung Cancer, Mesothelioma
Interventions
IMRT
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jun 25, 2026, 11:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

NCT03501069
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-418, TAK-418 Matching Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Glendale, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jun 25, 2026, 11:34 PM EDT
Completed No phase listed Observational

Sequence Effect in Parkinson's Disease

NCT00431366
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Phase 1 Interventional

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

NCT02549651
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
MEDI4736, tremelimumab, AZD9150
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
La Jolla, California • Baltimore, Maryland • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Jun 25, 2026, 11:34 PM EDT
Completed No phase listed Observational

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

NCT03788746
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
58
States / cities
Little Rock, Arkansas • Glendale, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Phase 2 Interventional

A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

NCT00655369
View directory record Official record
Conditions
Nonrestorative Sleep
Interventions
PD 0200390, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
52
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Jun 25, 2026, 11:34 PM EDT
Terminated Phase 1 Interventional

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

NCT06546553
View directory record Official record
Conditions
Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
Drug · Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT02125461
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MEDI4736, PLACEBO
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
60
States / cities
Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jun 25, 2026, 11:34 PM EDT
Completed Not applicable Interventional

The Effect of Low Frequency STN DBS on Sleep and Vigilance in Parkinson's Disease (PD) Patients

NCT01769690
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DBS stimulator setting alteration, virtual reality simulator
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Jun 25, 2026, 11:34 PM EDT